The Company has capitalized the costs associated with acquiring the exclusive worldwide license to develop and commercialize products comprising or containing the proprietary therapeutic compound ART27.13, formerly known as NEO1940 as an intangible asset at a value of $2,039 as of November 30, 2021, and August 31, 2021.

The amount capitalized consisted of a $1,500 payment and the fair value of 61,297 shares of common stock of $539. During the three months ended November 30, 2021, no additional costs met the criteria for capitalization as an intangible asset.